Earnings Releases·Nov 5, 2026, 4:07 PM ET

Health Catalyst — Third Quarter 2026 Earnings Summary

Total revenue for Q3 2026 fell 26% year-over-year to $56.283 million, while GAAP net income swung to a $40.496 million profit from a $22.229 million loss in the prior year period, driven by a $65.889 million gain on the sale of the Vitalware Business.
The company eliminated all outstanding debt totaling $153.251 million as of September 30, 2026, utilizing proceeds from the Vitalware divestiture and cash on hand to fully repay obligations and terminate the Credit Agreement.
Full-year 2026 guidance was reaffirmed, projecting total revenue between $246 million and $249 million, and Adjusted EBITDA between $18 million and $18.5 million.
Revenue headwinds were attributed to the divestiture of Vitalware and migration challenges from DOS to Ignite, resulting in a 26% decline in technology revenue and a 36% decline in professional services revenue for the quarter.
Management prioritizes client retention and the development of durable, profitable revenue streams, noting a $122.548 million goodwill impairment charge for the nine months ended September 30, 2026.